566 related articles for article (PubMed ID: 28578824)
1. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
[TBL] [Abstract][Full Text] [Related]
2. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
3. A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies.
Singh SK; Roeffen W; Andersen G; Bousema T; Christiansen M; Sauerwein R; Theisen M
Vaccine; 2015 Apr; 33(16):1981-6. PubMed ID: 25728318
[TBL] [Abstract][Full Text] [Related]
4. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based
Singh SK; Plieskatt J; Chourasia BK; Fabra-García A; Garcia-Senosiain A; Singh V; Bengtsson KL; Reimer JM; Sauerwein R; Jore MM; Theisen M
Front Immunol; 2020; 11():606266. PubMed ID: 33505395
[TBL] [Abstract][Full Text] [Related]
5. A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.
Alkema M; Smit MJ; Marin-Mogollon C; Totté K; Teelen K; van Gemert GJ; van de Vegte-Bolmer M; Mordmüller BG; Reimer JM; Lövgren-Bengtsson KL; Sauerwein RW; Bousema T; Plieskatt J; Theisen M; Jore MM; McCall MBB
BMC Med; 2024 Apr; 22(1):170. PubMed ID: 38649867
[TBL] [Abstract][Full Text] [Related]
6. Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display.
Crossey E; Frietze K; Narum DL; Peabody DS; Chackerian B
PLoS One; 2015; 10(7):e0132560. PubMed ID: 26147502
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
[TBL] [Abstract][Full Text] [Related]
8. A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system.
Lee SM; Hickey JM; Miura K; Joshi SB; Volkin DB; King CR; Plieskatt JL
Sci Rep; 2020 Jan; 10(1):395. PubMed ID: 31942034
[TBL] [Abstract][Full Text] [Related]
9. Engineering a Virus-Like Particle as an Antigenic Platform for a Pfs47-Targeted Malaria Transmission-Blocking Vaccine.
Yenkoidiok-Douti L; Williams AE; Canepa GE; Molina-Cruz A; Barillas-Mury C
Sci Rep; 2019 Nov; 9(1):16833. PubMed ID: 31727945
[TBL] [Abstract][Full Text] [Related]
10. Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.
Baldwin SL; Roeffen W; Singh SK; Tiendrebeogo RW; Christiansen M; Beebe E; Carter D; Fox CB; Howard RF; Reed SG; Sauerwein R; Theisen M
Vaccine; 2016 Apr; 34(19):2207-15. PubMed ID: 26994314
[TBL] [Abstract][Full Text] [Related]
11. Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45.
Kundu P; Semesi A; Jore MM; Morin MJ; Price VL; Liang A; Li J; Miura K; Sauerwein RW; King CR; Julien JP
Nat Commun; 2018 Oct; 9(1):4458. PubMed ID: 30367064
[TBL] [Abstract][Full Text] [Related]
12. Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants.
Roeffen W; Theisen M; van de Vegte-Bolmer M; van Gemert G; Arens T; Andersen G; Christiansen M; Sevargave L; Singh SK; Kaviraj S; Sauerwein R
Malar J; 2015 Nov; 14():443. PubMed ID: 26552428
[TBL] [Abstract][Full Text] [Related]
13. Fusion to Tetrahymena thermophila granule lattice protein 1 confers solubility to sexual stage malaria antigens in Escherichia coli.
Agrawal A; Bisharyan Y; Papoyan A; Bednenko J; Cardarelli J; Yao M; Clark T; Berkmen M; Ke N; Colussi P
Protein Expr Purif; 2019 Jan; 153():7-17. PubMed ID: 30081196
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
Kingston NJ; Kurtovic L; Walsh R; Joe C; Lovrecz G; Locarnini S; Beeson JG; Netter HJ
Vaccine; 2019 Mar; 37(12):1674-1684. PubMed ID: 30773400
[TBL] [Abstract][Full Text] [Related]
15.
Singh SK; Thrane S; Chourasia BK; Teelen K; Graumans W; Stoter R; van Gemert GJ; van de Vegte-Bolmer MG; Nielsen MA; Salanti A; Sander AF; Sauerwein RW; Jore MM; Theisen M
Front Immunol; 2019; 10():1256. PubMed ID: 31231386
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
17. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
[TBL] [Abstract][Full Text] [Related]
18. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.
Theisen M; Jore MM; Sauerwein R
Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178
[TBL] [Abstract][Full Text] [Related]
19. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
[TBL] [Abstract][Full Text] [Related]
20. Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins.
Singh K; Burkhardt M; Nakuchima S; Herrera R; Muratova O; Gittis AG; Kelnhofer E; Reiter K; Smelkinson M; Veltri D; Swihart BJ; Shimp R; Nguyen V; Zhang B; MacDonald NJ; Duffy PE; Garboczi DN; Narum DL
Commun Biol; 2020 Jul; 3(1):395. PubMed ID: 32709983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
